Regulatory Delay? Verisk Walks Away

Verisk terminated its definitive agreement to acquire AccuLynx after the FTC notified Verisk it hadn’t completed its review by the deal’s extended termination date of December 26, 2025. The deal didn’t sink over strategy or price — it ran into the corporate equivalent of “your meeting is still on hold".

From an investor lens, the most tangible immediate move is capital-structure housekeeping. Verisk said it will redeem $1.5 billion aggregate principal amount of senior notes issued for the planned acquisition at 101% of principal plus accrued and unpaid interest, and noted the redemption is required under a “special mandatory redemption” provision in the notes. Verisk also quantified the “back to normal” balance sheet view: pro forma leverage would have been 1.9x LTM adjusted EBITDA as of September 30, 2025.

Management used the moment to underline shareholder-friendly priorities rather than mourn a missed deal. CEO Lee Shavel reiterated Verisk’s “capital allocation discipline,” balancing investment in high-return opportunities while returning capital via dividend and repurchases, and said the company remains confident in delivering results in line with its long-term growth targets for 2025, 2026 and beyond. Verisk also disclosed that, as of September 30, it had $1.2 billion remaining under its share repurchase authorization—an important “what-now” datapoint for valuation-focused holders.

The only unresolved subplot is the paperwork sparring. AccuLynx notified Verisk it believes the termination is invalid, while Verisk “strongly disagrees” and says it intends to vigorously defend its position. For investors, that’s the key risk footnote, but the broader takeaway is that Verisk is trying to turn a delayed regulatory calendar into a reset - unwind acquisition financing, reaffirm targets, and keep the capital-return engine humming.

Disclaimer: This content is for informational and entertainment purposes only and does not constitute financial or investment advice. The information provided may be outdated or contain inaccuracies. Always conduct your own due diligence and consult a licensed financial advisor before making investment decisions. Investing involves risk, including the potential loss of principal. Unless explicitly stated otherwise, neither Equiscreen, LLC nor its beneficial owners hold any financial interest in the companies mentioned in our articles, and we do not receive compensation for including them. Equiscreen, LLC and its beneficial owners may buy or sell securities of any company referenced in our content at any time and without prior notice, and nothing published by Equiscreen, LLC should be interpreted as a recommendation to buy, sell, or hold any security. Any paid content or income-related materials will be clearly identified as “Sponsored” or “Advertorial,” and corresponding income disclosures can be found at the bottom of the page. For additional information, please contact [email protected].

Top Gainers

Top Losers

U.S. Commodities

2234 N Federal Hwy # 1022
Boca Raton, FL 33431

(561) 264-5726